Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfacetamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | DHFR | P00374 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfacetamide SCHEMBL28182511 | 1.00 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL15869608 | 0.98 | SMN1; SMN2 (0.93) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL28122264 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL40863 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL15567784 | 0.96 | SMN1; SMN2 (0.89) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL2503539 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL29207414 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL3912378 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL16097762 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 | |
| Sulfacetamide SCHEMBL28308067 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2DHFRTSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3760 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027255-A1 | Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same | BETTY YU SKIN TECH ADVISORS LLC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4658376-A1 | SKIN CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2025-12-10 | — | — | EP | claimed |
| US-12427151-B2 | Compositions and method of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-30 | — | — | US | claimed |
| EP-4615429-A1 | COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER | XMK Therapeutics Inc. (CA) | 2025-09-17 | — | — | EP | claimed |
| WO-2025125508-A1 | CORTEXOLONE-17ΑLPHA-PROPIONATE COMBINATIONS FOR TREATING ACNE | CASSIOPEA S.P.A. (IT) | 2025-06-19 | — | — | WO | claimed |
| EP-4101437-B1 | BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN EULIKAN BIOTECHNOLOGY CO LTD (CN) | 2025-06-11 | — | — | EP | claimed |
| EP-4562097-A2 | CROSS-LINKED TELECHELIC POLYMER COMPOSITIONS, METHODS OF PREPARATION THEREOF, AND METHODS OF USING SAME | Betty Yu Skin Technology Advisors, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119944018-A | Electrolyte additive, electrolyte, and preparation method and application of electrolyte | 纬景储能科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025088126-A1 | TOPICAL COMPOSITION COMPRISING AT LEAST TWO LIPIDS | LIPIDOR AB (SE) | 2025-05-01 | — | — | WO | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| EP-0512050-A4 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | — | 1993-04-21 | — | — | EP | claimed |
| EP-0512050-A1 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | THE UNIVERSITY OF KANSAS (US) | 1992-11-11 | — | — | EP | claimed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | claimed |
| US-5134127-A | Sulfoalkyl Ethers, Solubilizing Agents for Drugs | UNIVERSITY OF KANSAS (US) | 1992-07-28 | — | — | US | claimed |
| WO-1991011172-A1 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | THE UNIVERSITY OF KANSAS (US) | 1991-08-08 | — | — | WO | claimed |
| US-5008255-A | Aqueous composition having pH of 6.0 to 6.5 | ALCON LABORATORIES, INC. (US) | 1991-04-16 | — | — | US | claimed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| US-4136173-A | VEHICLES FOR OPHTHALMIC DRUGS | AMERICAN HOME PRODUCTS CORP. (US) | 1979-01-23 | — | — | US | claimed |
| US-4122158-A | FOR TREATMENT OF BURNS; BIODEGRADABLE HYDROPHOBIC POLYMER; SUSTAINED RELEASE | ALZA CORPORATION (US) | 1978-10-24 | — | — | US | claimed |
| US-3983209-A | HYDROPHOBIC BIOERODIBLE POLYMER, MICROBIOCIDE OR PROTEOLYTIC ENZYME | ALZA CORPORATION (US) | 1976-09-28 | — | — | US | claimed |